Ablynx: EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX

           Ablynx: EURONEXT INTRODUCES SPOTLIGHT OPTIONS ON ABLYNX

REGULATED INFORMATION

GHENT, Belgium, 15 July 2014 -Ablynx [Euronext Brussels: ABLX] today announced
that Euronext N.V. will introduce Spotlight Options on the shares of Ablynx
(option trading symbol: ABY). The options will be available as of today on the
derivatives market of Euronext Brussels.

Spotlight Options  are  a  special  segment  on  the  Amsterdam  and  Brussels 
derivatives markets of Euronext,  dedicated to the  development of new  option 
classes with  a short  maturity.  Through a  unique combination  of  Liquidity 
Provider support  and dedicated  promotion by  Sponsoring Brokers,  underlying 
assets with notable market  events or activity will  be put in the  spotlight. 
The liquidity in these option classes will be supported by Susquehanna.

Ablynx is a biopharmaceutical company engaged in the discovery and development
of NanobodiesĀ®, a novel class  of therapeutic proteins based on  single-domain 
antibody fragments, for  a range  of serious human  diseases in  the areas  of 
inflammation, haematology,  oncology and  pulmonology. The  Company  currently 
employs more than 300 people in its headquarters in Ghent, Belgium.

Dr Edwin Moses, Chief Executive Officer of Ablynx, commented:
"Ablynx has made tremendous progress since  the initial public listing of  the 
Company on Euronext  Brussels in  November 2007,  both on  an operational  and 
financial level. Since its IPO, Ablynx  has developed into one of the  leading 
biopharmaceutical companies in Europe  with more than 30  products in the  R&D 
pipeline of which  seven are  in clinical development,  partnerships with  six 
major pharma companies, a  strong cash position  and a free  float of 90%.  We 
believe that  the  introduction of  Spotlight  Options will  offer  additional 
investment and trading  possibilities, further increase  the liquidity of  our 
shares and improve the visibility of the Company in the financial markets."

Vincent Van Dessel, Chief Executive Officer of Euronext Brussels, added:
"We are pleased to announce the  introduction of Spotlight Options for  Ablynx 
on Euronext Brussels,  providing institutional and  retail investors with  new 
investment opportunities. The Ablynx Spotlight Option class will benefit  from 
the growing interest in Belgian options we have seen over the past year."

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of NanobodiesĀ®, a novel class  of therapeutic proteins based on  single-domain 
antibody  fragments,  for  a  range  of  serious  human  diseases,   including 
inflammation, haematology, oncology and pulmonary disease. Today, the  Company 
has more than 30 programmes in  the pipeline and seven Nanobodies in  clinical 
development. Ablynx  has  on-going  research  collaborations  and  significant 
partnerships with major pharmaceutical companies including AbbVie,  Boehringer 
Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
 +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

Euronext Brussels:

Jean-Yves Daxhelet
t: +32 2 213 13 03
e: jean-yves.daxhelet@interelgroup.com

pdf format of the press release

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire
HUG#1822671
 
Press spacebar to pause and continue. Press esc to stop.